Translating science to medicine: The case for physician-scientists
8 min read
The coronavirus disease 2019 (COVID-19) pandemic and resulting vaccines are a potent reminder of the definitive impact of biomedicine and the unique ability of a workforce steeped in both basic research and clinical medicine to respond to a medical crisis. However, the reminder arrives at a critical juncture, with fewer and fewer physicians trained in both biomedical research and clinical medicine. How we address this declining workforce will affect our ability to improve health and our readiness for the next global health emergency.
The current pandemic highlights how physicians who see patients, teach the next generation of doctors, and do research to understand disease are impaired by constraints on reimbursement, time, and funding. We fear that physician-scientists may dwindle toward obsolescence under the harsh realities of 21st-century health care.
This modern era that sees us diagnosing disease by genome sequencing, developing RNA-based therapeutics, and finding once-unimaginable cancer cures reinforces the necessity of the physician-scientist to continue the momentum of discovery and its translation to public health.
PITFALLS IN THE PATHWAY
Many medical students were inspired to take the physician-scientist path by attending physicians and other mentors who were both clinicians and researchers. Today, encounters with clinicians who do research are increasingly uncommon. Funding and recertification challenges have led some physician-scientists to abandon their clinical practice for full-time research. Clinical and hospital trainees lack role models and mentors who see patients, teach, and do research.
The cost of medical school and postgraduate expenses continue to rise, yet forgiveness programs continue to decline. Post-training salary support is provided for clinicians, but the physician-scientist is required to garner external grant support to fund not only their research program but also a major portion of their salary, forcing many to devote 40 to 50% of valuable time to grant writing.
A MULTIPRONGED STRATEGY TO REBUILD
It would be easy to succumb to the discouragement of these trends. However, our obligation to patients is too great, the need to discover is too strong, and the talent pool is too promising. We offer the following multipronged strategy to rebuild the physician-scientist pathway.
An immersive research experience for medical trainees
Science is foundational to medicine. Whereas exposure to core principles is critical, the depth of engagement needs to be tailored to a student’s interest, with medical schools coupling a core curriculum with intensive experiences in specific research areas. Ideally, aspiring physician-scientists would receive intensive basic science exposure and exposure to research careers at multiple points along the training continuum.
We advocate for increased access to opportunities such as formal Medical Scientist Training Programs and other immersive research experiences and for the expansion of year-long research programs outside of preclinical and clinical training. Prestigious programs established by the U.S. National Institutes of Health (NIH), the Howard Hughes Medical Institute (HHMI), and the Sarnoff Cardiovascular Research Foundation have provided stipends to medical students to take a medical research gap year. However, the NIH-funded program requires travel to Bethesda, Maryland, creating logistical issues for many. HHMI had allowed students to conduct research at institutions of their choosing but unfortunately terminated its program in 2019. The Sarnoff Cardiovascular Research Foundation program and a few other scholarships are available, but there are far too few funded positions for medical students to receive extensive research training.
An annual subsidy of approximately $6 million would support an additional 100 medical students per year to spend a gap year in a research laboratory. To put this amount into perspective, $6 million is ~0.01% of the $40.3 billion NIH budget, 0.009% of the White House $65 billion pandemic-preparedness plan, or 0.003% of the pharmaceutical industry’s $180 billion research and development budget. In other words, the cost of placing 100 medical students in research laboratories for 1 year amounts to a mere rounding error in government and industry budgets. However, this strategy would provide substantial return on investment by training physician-scientists who are essential to meeting our nation’s biomedical research mission.
Optimal timing of research for medical trainees is much debated. However, there is not just one ideal time for training physician-scientists. Some students are exposed to science early, while others are not. To build an inclusive physician-scientist workforce, we must ensure that medical trainees have adequate exposure to the excitement of research, enabling them to seek answers to medicine’s many unanswered questions.
Lower financial barriers
In addition to loan forgiveness, young physician-scientists need a living wage. They need stipend support for research training during residency and fellowship, educational debt reduction through programs such as NIH’s Loan Repayment Program, financial support for family and dependent care, and funding for the transition to their first independent faculty position. Although funding from NIH and nonprofit organizations such as the Burroughs Wellcome Fund and Doris Duke Charitable Foundation provide some support, funding remains insufficient to remove the financial burden to entering and committing to the physician-scientist pathway.
Restoring the educators and mentors
Building a leak-free physician-scientist network
We call for the formation of a tightly woven network of nonprofit, academic, and clinical institutions to ally with organizations such as the Physician-Scientist Support Foundation. The goal is to advocate for and monitor the restoration of basic science to the curriculum; to reincentivize faculty and mentors; and to make available funding, debt forgiveness, and research opportunities for physician-scientists. This network will ensure that funding and support are available for the entirety of the pipeline, from student to professor. The network will be an advocate for physician-scientists, changing the leaky pipeline of physician-scientists to one that no longer leaks.
CATALYZING A NEW GENERATION OF INVESTIGATORS
One hundred years ago, the devastating Spanish flu pandemic and a world at war gave birth to the physician-scientist. Today, COVID-19 and the war against science call for a reforging of our profession. We must ask ourselves: How strong is our commitment to supporting the successor generation and to ensuring a critical supply chain of physician-scientists that is agile and sustainable?
We end where it begins: The task to replenish the physician-scientist pipeline starts in medical school. A coordinated, nonprofit network will catalyze a new and resilient generation of physician-scientists who are research-centered and patient-centered, fortified by their diversity, and uniquely driven to uncover the inner workings of biology that will improve human health.
Paul J. Utz, Mukesh K. Jain, Vivian G. Cheung, Brian K. Kobilka, Robert Lefkowitz, Tadataka Yamada, and Victor J. Dzau
Acknowledgments
This article is dedicated to the memory of Tadataka Yamada, a champion, leader, and friend of physician-scientists. We thank S. Dickow for expert administrative assistance and the participants at the National Academy of Medicine Working Meeting for insights into physician-scientist career pathways.
Funding: P.J.U. was funded by a Burroughs Wellcome Fund Physician Scientist Institutional Award. The Physician Scientist Support Foundation was funded by Doris Duke Charitable Foundation.
Competing interests: B.K.K. is a cofounder of and paid consultant for ConfometRx Inc. V.J.D. has served as a member of the board of Alnylam Pharmaceuticals and Medtronic Inc. P.J.U. serves as a paid consultant of 4D Molecular Therapeutics, Immunic, and Seronova.
https://www.science.org/doi/10.1126/scitranslmed.abg7852
